Intellia Therapeutics (NTLA) Research & Development (2015 - 2026)
Intellia Therapeutics (NTLA) reported Research & Development of $80.7 million for Q1 2026, down 25.54% year-over-year from $108.4 million in Q1 2025, and down 8.93% on a QoQ basis from $88.7 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Research & Development data on file, last reported at $80.7 million in Q1 2026.
- Quarterly Research & Development fell 25.54% year-over-year to $80.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $361.2 million (down 21.97% YoY) and the FY2025 annual result came in at $388.9 million, down 16.61% from the prior year.
- Research & Development retreated to $80.7 million in Q1 2026 per NTLA's latest filing, from $88.7 million in the prior quarter.
- Across five years, Research & Development topped out at $133.1 million in Q1 2022 and bottomed at $80.7 million in Q1 2026.
- The 5-year median for Research & Development is $108.4 million (2025), against an average of $105.4 million.
- The widest annual swing landed in 2022, when Research & Development surged 238.87%; it then dropped 27.03% in 2023.
- Tracing NTLA's Research & Development over 5 years: stood at $100.0 million in 2022, then increased by 8.94% to $109.0 million in 2023, then grew by 7.25% to $116.9 million in 2024, then slipped by 24.15% to $88.7 million in 2025, then declined by 8.93% to $80.7 million in 2026.
- Per Business Quant, the three latest NTLA Research & Development figures stand at $80.7 million (Q1 2026), $88.7 million (Q4 2025), and $94.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 80.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.74 Mn |
| Dec 31, 2025 | 88.65 Mn |
| Sep 30, 2025 | 94.75 Mn |
| Jun 30, 2025 | 97.04 Mn |
| Mar 31, 2025 | 108.43 Mn |
| Dec 31, 2024 | 116.88 Mn |
| Sep 30, 2024 | 123.38 Mn |
| Jun 30, 2024 | 114.21 Mn |
| Mar 31, 2024 | 111.85 Mn |
| Dec 31, 2023 | 108.98 Mn |
| Sep 30, 2023 | 113.70 Mn |
| Jun 30, 2023 | 115.28 Mn |
| Mar 31, 2023 | 97.12 Mn |
| Dec 31, 2022 | 100.03 Mn |
| Sep 30, 2022 | 96.65 Mn |
| Jun 30, 2022 | 90.20 Mn |
| Mar 31, 2022 | 133.10 Mn |
| Dec 31, 2021 | 71.16 Mn |
| Sep 30, 2021 | 60.49 Mn |
| Jun 30, 2021 | 58.88 Mn |
| Mar 31, 2021 | 39.28 Mn |
| Dec 31, 2020 | 38.23 Mn |
| Sep 30, 2020 | 39.76 Mn |
| Jun 30, 2020 | 37.77 Mn |
| Mar 31, 2020 | 34.65 Mn |
| Dec 31, 2019 | 31.73 Mn |
| Sep 30, 2019 | 27.51 Mn |
| Jun 30, 2019 | 25.46 Mn |
| Mar 31, 2019 | 23.71 Mn |
| Dec 31, 2018 | 19.92 Mn |
| Sep 30, 2018 | 23.24 Mn |
| Jun 30, 2018 | 23.47 Mn |
| Mar 31, 2018 | 22.49 Mn |
| Dec 31, 2017 | 21.17 Mn |
| Sep 30, 2017 | 17.48 Mn |
| Jun 30, 2017 | 15.57 Mn |
| Mar 31, 2017 | 13.43 Mn |
| Dec 31, 2016 | 11.33 Mn |
| Sep 30, 2016 | 7.86 Mn |
| Jun 30, 2016 | 7.42 Mn |
| Mar 31, 2016 | 5.23 Mn |
| Dec 31, 2015 | 4.38 Mn |
| Sep 30, 2015 | 3.46 Mn |
| Jun 30, 2015 | 1.97 Mn |
| Mar 31, 2015 | 1.37 Mn |